SOAT inhibition can block the E1S-stimulated proliferation of T47D breast cancer cells and, therefore, in addition to the carriers of the OATP carrier family, can be regarded as a novel potential drug target for anti-proliferative breast cancer therapy. Here, SLC10A6 is linked to breast carcinoma.